drugset / Trial / NCT04135833

A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711

NCT04135833

Phase 1 Completed 31 enrolled Beta Pharma, Inc.
Non-randomizedParallel-groupOpen-labelOther

Summary

This is a phase I study to assess the effect of itraconazole and rifampicin on the pharmacokinetic parameters of BPI-7711 in Chinese healthy volunteers.

Timeline

Start
2019-12-12
Primary completion
2020-07-22
Completion
2020-07-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg
Subject Rifampin Small molecule 600 mg
Subject rezivertinib Small molecule 60 mg
Subject rezivertinib Small molecule 180 mg